Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regenxbio Inc (RGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,000,791
  • Shares Outstanding, K 36,611
  • Annual Sales, $ 218,510 K
  • Annual Income, $ 99,940 K
  • 60-Month Beta 0.47
  • Price/Sales 9.17
  • Price/Cash Flow 21.31
  • Price/Book 3.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.83
  • Number of Estimates 2
  • High Estimate -0.77
  • Low Estimate -0.90
  • Prior Year 3.00
  • Growth Rate Est. (year over year) -127.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.25 +6.63%
on 04/17/19
63.21 -13.54%
on 03/20/19
-3.71 (-6.36%)
since 03/18/19
3-Month
40.24 +35.81%
on 01/28/19
63.21 -13.54%
on 03/20/19
+7.53 (+15.98%)
since 01/18/19
52-Week
35.65 +53.30%
on 04/25/18
85.10 -35.78%
on 07/10/18
+14.15 (+34.94%)
since 04/18/18

Most Recent Stories

More News
REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 54.65 (-0.13%)
ARPO : 0.98 (+1.36%)
4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
ONCE : 110.62 (-0.08%)
SRPT : 116.64 (-1.76%)
OPHT : 1.39 (-0.71%)
NITE : 25.51 (+0.04%)
RGNX : 54.65 (-0.13%)
BOLD : 38.90 (+0.96%)
New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of UnitedHealth Group Incorporated...

NAV : 34.74 (+0.93%)
ATNX : 11.06 (-1.78%)
RARE : 64.43 (-0.43%)
PARR : 19.01 (-0.63%)
RGNX : 54.65 (-0.13%)
UNH : 221.75 (+2.26%)
REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 54.65 (-0.13%)
REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher

REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

BDSI : 4.65 (-0.64%)
RGNX : 54.65 (-0.13%)
REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights

-- Announces updates from recently expanded RGX-314 Phase I/IIa trial for wet AMD

RGNX : 54.65 (-0.13%)
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
ONCE : 110.62 (-0.08%)
RGNX : 54.65 (-0.13%)
EDIT : 25.80 (+0.31%)
5 Gene Therapy Stocks to Enrich Your Portfolio

Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
ONCE : 110.62 (-0.08%)
RGNX : 54.65 (-0.13%)
EDIT : 25.80 (+0.31%)
RHHBY : 32.6900 (-0.09%)
REGENXBIO to Host RGX-314 Program Analyst and Investor Event with Leading Retina Specialists

REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 54.65 (-0.13%)
Market Trends Toward New Normal in Keysight Technologies, Alamos Gold, ADT, SecureWorks, REGENXBIO, and Tetra Technologies -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Keysight Technologies Inc....

ADT : 6.65 (-0.30%)
AGI : 4.70 (-1.26%)
KEYS : 89.84 (+1.74%)
SCWX : 18.44 (-4.90%)
TTI : 2.44 (-0.41%)
RGNX : 54.65 (-0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade RGNX with:

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

2nd Resistance Point 57.80
1st Resistance Point 56.23
Last Price 54.65
1st Support Level 52.56
2nd Support Level 50.46

See More

52-Week High 85.10
Fibonacci 61.8% 66.21
Fibonacci 50% 60.38
Last Price 54.65
Fibonacci 38.2% 54.54
52-Week Low 35.65

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar